Setup News Ticker
Searching for 'Price'. (Return)

Yahoo BusinessJul 13, 2020
3 "Strong Buy" Penny Stocks That Could Deliver Massive Returns
Investor focus has landed squarely on the surge in new COVID-19 cases and its threat to economic reopenings, but there's another possibility being ignored. According to Morgan Stanley equity strategist Mike Wilson, even though the market is expecting economic activity to decline, earnings could get a major boost."Cautious investors may be overlooking the potential for operating leverage to fuel an earnings rebound... Aggressive cost-cutting in a downturn is what creates the powerful operating leverage when the economy recovers," Wilson commented.While unemployment has skyrocketed during the coronavirus crisis, Wilson argues operating leverage was already dropping before the pandemic's onset. "It's also a classic feature of late-cycle economic expansions. My point is that many companies were already exhibiting negative operating leverage pre-COVID-19. This gives me confidence that Q2 will likely be the trough for earnings growth," he explained.Bearing this in mind, some investors are on the hunt, looking to snap up compelling names before shares re-embark on an upward trajectory. For the more risk-tolerant, focus has locked in on penny stocks, or tickers trading for less than $5 per share. The appeal is clear; the bargain price tag means you can get more bang for your buck and even what feels like inconsequential share price appreciation can result in huge percentage gains.What's the flip side? Minor share price depreciation can fuel major percentage losses. By nature of these massive movements, penny stocks are no

Yahoo BusinessJul 13, 2020
Why Vaxart's Stock Is Trading Higher Today
Vaxart Inc (NASDAQ: VXRT) shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.The company also raised about $90 million in gross proceeds through at-the-market-facility.Vaxart is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. Geographically all the business activity is functioned through the region of the US.Vaxart shares were trading up 50.25% at $11.99 at the time of publication on Monday. The stock has a 52-week high of $14.30 and a 52-week low of 25 cents.Latest Ratings for VXRT DateFirmActionFromTo Jul 2020B. Riley FBRInitiates Coverage OnBuy Apr 2020HC Wainwright & Co.ReiteratesBuy Jun 2019H.C. WainwrightInitiates Coverage OnBuy View More Analyst Ratings for VXRT View the Latest Analyst RatingsSee more from Benzinga * 4 Cybersecurity Investment Opportunities Tied To The Rise In Online Threats * With E-Commerce Shift Underway, BofA Has High Expectations For PayPal's Q2 * Why Herbalife's Stock Is Trading Higher Today(C) 2020 Benzinga does not provide investment advice. All rights reserved.

StockMarket rise Tesla Today earnings
Coronaviruscases rise WHO latest vaccine
StocksRise Earnings These Markets Pfizer
MarketStock earnings Stocks rise Monday
Chinasanctions lawmakers claims South Sea
COVID-19Company vaccine Pfizer BioNTech York
BroncoFord Reveal off-road Jeep Years
Risecoronavirus futures earnings cases shares
TeslaStock Model Y biggest Musk
Sharesrise European turns EU recovery

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News Analysis Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News - China, Economy & Trade - Financial Markets - Hedge Funds - Telecoms - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC